11. MYD88 L265P mutation detected by digital PCR as a prognostic factor in patients with diffuse large B-cell lymphoma in rituximab era. (October 2020) Authors: Nishimura, Noriko; Takeuchi, Kengo; Asaka, Reimi; Tuyama, Naoko; Inoue, Norihito; Kusano, Yoshiharu; Mishima, Yuko; Yokoyama, Masahiro; Terui, Yasuhito Journal: Leukemia research Issue: Volume 97(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
12. Non-gastric advanced mucosa-associated lymphoid tissue (MALT) lymphoma has worse prognosis than gastric MALT lymphoma even when treated with rituximab-containing chemotherapy. Issue 9 (September 2013) Authors: Ueda, Kyoko; Terui, Yasuhito; Yokoyama, Masahiro; Sakajiri, Sakura; Nishimura, Noriko; Tsuyama, Naoko; Takeuchi, Kengo; Hatake, Kiyohiko Journal: Leukemia & lymphoma Issue: Volume 54:Issue 9(2013:Sep.) Page Start: 1928 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
13. Phase I study of obinutuzumab (GA101) in Japanese patients with relapsed or refractory B‐cell non‐Hodgkin lymphoma. Issue 1 (12th November 2012) Authors: Ogura, Michinori; Tobinai, Kensei; Hatake, Kiyohiko; Uchida, Toshiki; Suzuki, Tatsuya; Kobayashi, Yukio; Mori, Masakazu; Terui, Yasuhito; Yokoyama, Masahiro; Hotta, Tomomitsu Journal: Cancer science Issue: Volume 104:Issue 1(2013:Jan.) Page Start: 105 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
14. Phase I study of OPB‐51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies. Issue 7 (25th May 2015) Authors: Ogura, Michinori; Uchida, Toshiki; Terui, Yasuhito; Hayakawa, Fumihiko; Kobayashi, Yukio; Taniwaki, Masafumi; Takamatsu, Yasushi; Naoe, Tomoki; Tobinai, Kensei; Munakata, Wataru; Yamauchi, Takeshi; Kageyama, Akiko; Yuasa, Miyuki; Motoyama, Masaaki; Tsunoda, Takeshi; Hatake, Kiyohiko Journal: Cancer science Issue: Volume 106:Issue 7(2015:Jul.) Page Start: 896 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
15. Phase I study of OPB‐51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies. Issue 7 (25th May 2015) Authors: Ogura, Michinori; Uchida, Toshiki; Terui, Yasuhito; Hayakawa, Fumihiko; Kobayashi, Yukio; Taniwaki, Masafumi; Takamatsu, Yasushi; Naoe, Tomoki; Tobinai, Kensei; Munakata, Wataru; Yamauchi, Takeshi; Kageyama, Akiko; Yuasa, Miyuki; Motoyama, Masaaki; Tsunoda, Takeshi; Hatake, Kiyohiko Journal: Cancer science Issue: Volume 106:Issue 7(2015:Jul.) Page Start: 896 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
16. Phase I, multicenter, dose‐escalation study of avadomide in adult Japanese patients with advanced malignancies. Issue 1 (26th November 2020) Authors: Hatake, Kiyohiko; Chou, Takaaki; Doi, Toshihiko; Terui, Yasuhito; Kato, Harumi; Hirose, Takayuki; Seo, Sachiko; Pourdehnad, Michael; Ogaki, Yumi; Fujimoto, Hiroshi; Hagner, Patrick R.; Yamamoto, Kazuhito Journal: Cancer science Issue: Volume 112:Issue 1(2021) Page Start: 331 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
17. Phase I/II study of bortezomib‐melphalan‐prednisolone for previously untreated Japanese patients with multiple myeloma. Issue 7 (27th May 2013) Authors: Ogawa, Yoshiaki; Suzuki, Kenshi; Sakai, Akira; Iida, Shinsuke; Ogura, Michinori; Tobinai, Kensei; Matsumoto, Morio; Matsue, Kosei; Terui, Yasuhito; Ohashi, Kazuteru; Ishii, Masami; Mukai, Harumi Y.; Ando, Kiyoshi; Hotta, Tomomitsu Journal: Cancer science Issue: Volume 104:Issue 7(2013:Jul.) Page Start: 912 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
18. Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma. Issue 1 (25th June 2020) Authors: Narita, Yoshitaka; Nagane, Motoo; Mishima, Kazuhiko; Terui, Yasuhito; Arakawa, Yoshiki; Yonezawa, Hajime; Asai, Katsunori; Fukuhara, Noriko; Sugiyama, Kazuhiko; Shinojima, Naoki; Kitagawa, Junsaku; Aoi, Arata; Nishikawa, Ryo Journal: Neuro-oncology Issue: Volume 23:Issue 1(2021) Page Start: 122 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
19. Phase II study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T‐cell lymphoma. Issue 6 (3rd May 2021) Authors: Kawai, Hidetsugu; Ando, Kiyoshi; Maruyama, Dai; Yamamoto, Kazuhito; Kiyohara, Eiji; Terui, Yasuhito; Fukuhara, Noriko; Miyagaki, Tomomitsu; Tokura, Yoshiki; Sakata‐Yanagimoto, Mamiko; Igarashi, Tadahiko; Kuroda, Junya; Fujita, Jiro; Uchida, Toshiki; Ishikawa, Takayuki; Yonekura, Kentaro; Kato, Ko... Journal: Cancer science Issue: Volume 112:Issue 6(2021) Page Start: 2426 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
20. Prognostic value of high thymidine kinase activity in patients with previously untreated diffuse large B-cell lymphoma treated by rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone. Issue 11 (November 2013) Authors: Suzuki, Kazuhito; Terui, Yasuhito; Yokoyama, Masahiro; Ueda, Kyoko; Nishimura, Noriko; Mishima, Yuko; Sakajiri, Sakura; Tsuyama, Naoko; Takeuchi, Kengo; Hatake, Kiyohiko Journal: Leukemia & lymphoma Issue: Volume 54:Issue 11(2013:Nov.) Page Start: 2412 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗